Side population rather than CD133+ cells distinguishes enriched tumorigenicity in hTERT-immortalized primary prostate cancer cells

Molecular Cancer

Research

Karen Marie Wolcott¹  Clayton Yates²  Honghe Wang²  Virginetta Cannon²  Jianjun Zhou³  Hongbin Song⁴ 

[1] Biomedical Instrumentation Center, Uniformed Services University of the Health Sciences, 20814, Bethesda, MD, USA;Department of Biology and Center for Cancer Research, Tuskegee University, 36088, Tuskegee, AL, USA;Department of Biology and Center for Cancer Research, Tuskegee University, 36088, Tuskegee, AL, USA;Biomedical Instrumentation Center, Uniformed Services University of the Health Sciences, 20814, Bethesda, MD, USA;Institute of Disease Control and Prevention, Academy of Military Medical Science, 100071, Beijing, China;

关键词: Cancer Stem Cells;    CD133;    Side population (SP);    prostate cancer;   

DOI  :  10.1186/1476-4598-10-112

 received in 2010-05-14, accepted in 2011-09-14,  发布年份 2011

来源: Springer

【 摘 要 】

BackgroundSubpopulations of cancer cells with the capacity of generating solid tumors have been characterized. In various cancer types, including prostate cancer cells, a side population (SP) and CD133-expressing cells have been proposed as containing a population cancer cells with stem-like ability. Therefore the aim of this work was to determine, in prostate cancer cell lines, the frequency and tumorigenic potential of SP and CD133+ cells.ResultsIn vitro 2D colony-forming assay and sphere-forming assay, Flow cytometry analysis and magnetic cell sorting were utilized to sort CD133+, CD133- and Side population (SP) cells. Our findings indicate that CD44 and integrin α-6 are uniformly expressed in the hTERT cell lines; however, CD133 is expressed only in a small population (< 0.1%). FACS-sorted CD133+ and CD133- cells exhibited similar tumorigenicity in vitro and in vivo. Additionally, for the hTERT cells, SP rather than CD133 expression showed an 8-fold enhanced tumorigenic potential. The data suggest that SP cells, rather than those with CD133 marker, contain the rare population of CSC capable of producing prostate tumors.ConclusionCollectively, our data suggest that although CD133 is expressed only in a small population of hTERT-immortalized prostate cancer cells, it is not likely to be associated with stem cells, as CD133- and CD133+ cells exhibited similar tumorigenicity. However, SP isolated cells, appear to be enriched with tumorigenic stem-like cells capable of generating palpable tumors.

【 授权许可】

Unknown   
© Zhou et al; licensee BioMed Central Ltd. 2011. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.